News - Precision Biologics

14MarMarch 14, 2023

Dr. Philip M. Arlen gives keynote address on NEO-201 Developments at World Antibody Congress, San Diego, CA, March 20th, 2023

Dr. Philip M. Arlen, President and CEO, Precision Biologics, gives keynote address entitled “Preclinical/Clinical Development...

14DecDecember 14, 2022

Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)

READ ARTICLE

01DecDecember 1, 2022

Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201

Precision Biologics, Inc. publishes paper on latest findings of the unique target that NEO-201 recognizes,...

09NovNovember 9, 2022

Precision Biologics To Deliver Poster Presentations On Clinical And Scientific Programs At Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present...

09NovNovember 9, 2022

SITC 2022 – Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022

Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...

04OctOctober 4, 2022

Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022

Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...

05JunJune 5, 2022

Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022

Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...

07AprApril 7, 2022

Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at Oxford Global’s 2021 Biomarkers UK Conference

Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at...

22MarMarch 22, 2022

Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....

09MarMarch 9, 2022

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics, San Diego, March 9, 2022

Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...